1240471-17-3

Upstream product

• 1240471-09-3 1-(2'-deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluoro-4'-C-hydroxymethyl-β-D-arabinofuranosyl)uracil 
• 144822-64-0 1-(2'-deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluoro-β-D-arabinofuranosyl)uracil 
• 4202-14-6 dimethyl (2-oxopropyl)phosphonate 
• 1240471-13-9 1-(2'-deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluoro-4'-C-hydroxymethyl-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-β-D-arabinofuranosyl)uracil 
• 69123-94-0 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)uracil 

Downstream Products

• 1240471-20-8 1-(2'-deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluoro-4'-C-ethynyl-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-β-D-arabinofuranosyl)cytosine 

Relevant academic research and scientific papers

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus infection with one or more nucleosides, nucleotides and nucleotide analogs.

Synthesis and anti-HIV activity of 2′-deoxy-2′-fluoro-4′-C-ethynyl nucleoside analogs

Based on the favorable antiviral profiles of 4′-substituted nucleosides, novel 1-(2′-deoxy-2′-fluoro-4′-C-ethynyl-β-d-arabinofuranosyl)-uracil (1a), -thymine (1b), and -cytosine (2) analogs were synthesized. Compounds 1b and 2 exhibited potent anti-HIV-1 activity with IC50 values of 86 and 1.34 nM, respectively, without significant cytotoxicity. Compound 2 was 35-fold more potent than AZT against wild-type virus, and also retained nanomolar antiviral activity against resistant strains, NL4-3 (K101E) and RTMDR. Thus, 2 merits further development as a novel NRTI drug.